Recon Strategy
Contact

Insights

Fifteen+ years of
Healthcare thinking.

Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.

Sector
All
NEJM opinion

The growth of small molecule drug classes over time

  • Biopharma
Modern drug discovery is largely based on the identification and valid…

Read more